Indeed, we previously demonstrated that 400 mg/kg HP-β-CD subcutaneously administered every week had no effects on hepatic disorder, such as serum ALT elevation and histological changes, in Npc1−/− mice [7]. This evidence concerns the gene NPC1 and liver disorder.